Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Nitinol Medical (NASDAQ: NMTI) -- Ignore unavailable to you. Want to Upgrade?

To: Volsi Mimir who wrote (7)	11/14/1997 9:37:00 PM
From: Volsi Mimir	Respond to of 18

Reuters, Friday, November 14, 1997 at 17:07 BOSTON, Nov 14 (Reuters) - Nitinol Medical Technologies Inc said Friday said that two studies involving its product CardioSEAL have shown positive results. It said that in a multi-center clinical trial for the device, which is designed to close holes in the heart, 96 percent out of 82 patients implanted with the product showed a "clinically successful result." The result of the study was reported by Evan Zahn, a doctor at Miami's Children's Hospital, Miami, Fla., in a talk at the annual meeting of the American Heart Association, it said. The preliminary data suggests that CardioSEAL is a "safe and effective" device for transcatheter to close atrial septal defects, Nitinol quoted Zahn as saying. In another study, Nitinol said that Dr. Kathy Jenkins, in a report on a study on the use of CardioSEAL for high risk patients sponsored by Children's Hospital in Boston, said findings suggest that the device "will be an important alternative to surgery for high risk patients." Thomas Tully, Nitinol president and chief executiv, said the company was encouraged by clinical experience on the use of thr device. He said that further investigations of the device are ongoing in North America. CardioSEAL is commercially available in most countries elsewhere in the world, he said. Copyright 1997, Reuters News Service

To: Volsi Mimir who wrote (7)	11/14/1997 9:39:00 PM
From: Volsi Mimir	Respond to of 18

PR Newswire, Thursday, November 13, 1997 at 16:40 BOSTON, Nov. 13 /PRNewswire/ -- Nitinol Medical Technologies, Inc. (Nasdaq-NNM: NMTI) today announced preliminary clinical results for the Company's CardioSEAL(TM) Septal Occluder presented by two investigators at the annual meeting of the American Heart Association held in Orlando, Florida. Evan M. Zahn, M.D. from Miami Children's Hospital, Miami, Florida, reported the initial results from a multi-center North American clinical trial for use of the CardioSEAL for transcatheter closure of isolated secundum atrial septal defects ("ASD") in patients considered to be candidates for open heart surgical repair. Of 82 patients implanted with the CardioSEAL, 96% achieved a clinically successful result. Dr. Zahn concluded that this preliminary data suggests that the CardioSEAL is a safe and effective device for transcatheter ASD closure. Kathy J. Jenkins, M.D. reported on the initial experience with the use of the CardioSEAL for transcatheter closure of complex cardiac defects in high risk patients in a study sponsored by Children's Hospital in Boston. Patients enter the trial following the determination by an independent medical review committee that they are at high risk of morbidity/mortality if treated surgically. Dr. Jenkins reported on 117 patients implanted with 162 CardioSEAL devices between May 1996 and August 1997 for a variety of cardiac defects, including ASD, ventricular septal defects, patent foramen ovale (PFO) and fenestrated fontan. Dr. Jenkins concluded that the findings suggest that the CardioSEAL will be an important alternative to surgery for high risk patients. Thomas M. Tully, President and Chief Executive Officer of Nitinol Medical Technologies commented, "We continue to be very encouraged by the worldwide clinical experience with the CardioSEAL Septal Occluder. The preliminary findings reported at the American Heart Association meeting suggest both the effectiveness of the CardioSEAL and the potential versatility of the device for a variety of clinical applications. Further investigations of the device are ongoing in North America. The CardioSEAL is commercially available in most countries elsewhere in the world." Nitinol Medical Technologies, Inc. designs, develops, and markets innovative medical devices that utilize advanced technologies and are delivered by minimally invasive procedures. The Company's products are designed to offer alternative approaches to existing complex treatments, thereby reducing patient trauma, shortening procedure, hospitalization and recovery times, and lowering overall treatment costs. The Company's patented medical devices include self-expanding stents, vena cava filters and septal repair devices. This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties or other factors which may cause actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Factors that might cause such a difference include, but are not limited to, those discussed under the heading "Certain Factors That May Affect Future Results" included in the Management's Discussion and Analysis of Financial Condition and Results of Operations in the Company's Annual Report on Form 10- K for the year ended December 31, 1996 and in the Company's 1996 Annual Report to Stockholders, and in documents subsequently filed by the Company with the Securities and Exchange Commission. To receive Nitinol's latest news release and other corporate documents via FAX -- no cost -- please dial 1-800-PRO-INFO. Enter Nitinol's ticker-NMTI. SOURCE Nitinol Medical Technologies, Inc. -0- 11/13/97 /CONTACT: Thomas M. Tully, President & CEO of Nitinol Medical Technologies, 617-737-0930; General, Paula Schwartz, Analysts, Brian Gill, Media, Deanne Eagle, 212-661-8030, or Analysts, Kathy Brunson, 312-266-7800, all of The Financial Relations Board/